Casopís lékar̆ů c̆eských
-
Casopís lékar̆ů c̆eských · Jan 2011
[Preparation of the Eighth Framework Programme of the European Union--Health Priority. European Commission organizes proposal of aims in biomedical research prospecting to 2020].
Eighth framework programme (FP8) of the European Union for years 2014-2020 undergoes the preparatory process. The overview presents current status of the programme preparation. European Commission organized three workshops (-omics in personalised medicine, 4D biology for health and disease, and Stratification biomarkers in personalised medicine) with the purpose to bring together experts from different fields to build a 2020 vision, and to identify the research needs for next years.
-
Casopís lékar̆ů c̆eských · Jan 2011
[Conflict of interest: the World Medical Association statement].
This article presents a translation of the World Medical Association Statement on Conflict of Interest (2009) and Statement concerning the Relationship between Physicians and Commercial Enterprises (2009). The introduction illuminates the objectives of this recommendation in the context of healthcare in the Czech Republic.
-
Casopís lékar̆ů c̆eských · Jan 2011
Biography Historical Article[Nobel Prize laureates. Robert William Holley (1922-1993)].
-
Casopís lékar̆ů c̆eských · Jan 2010
[Means of early diagnostics and subsequent care for critically ill patient].
The delayed identification of an unstable patient may lead to the delayed management or the delayed transfer of the patient to the Intensive care unit and this can be related to the increase in the risk of death. ⋯ The introducing of the specialized teams as Medical emergency team or more complex Intensive care unit outreach service is related to the increased chance of unstable patient to meet earlier medical support specialized in intensive care. The above mentioned specialized teams may--according to some data--reduce the hospital mortality, incidence of cardiorespiratory arrest as well as the incidence of the unplanned Intensive care unit admissions.
-
Casopís lékar̆ů c̆eských · Jan 2010
Review[Drug treatment of obesity--current situation and perspectives].
Pharmacotherapy of obesity should be an integral part of the comprehensive obesity management program which includes diet, exercise and cognitive behavioural intervention. Currently available antiobesity drugs result in only modest weight loss, however it is still accompanied by reduction of cardiometabolic health risks. In the past several antiobesity drugs were removed from the market because of serious adverse effects (psychostimulatory, cardiovascular, pulmonary hypertension, valvular disease, depression, addiction etc.). ⋯ However, previous experiences that antiobesity drug combinations (e.g. fenfluramine/phentermine) may also potentiate adverse events should be carefully considered in the evaluation of recently tested compounds. Administration of physiological doses of gut hormones - derived appetite regulating agents seems to be a promising, efficient, specific and thus, low side-effect approach in the treatment of obesity. To confirm the strong role of antiobesity drugs in the treatment of obesity and its complications further long-term studies evaluating their effect on morbidity and mortality end points in appropriate target populations are needed.